Country: United States
Language: English
Source: NLM (National Library of Medicine)
MEMANTINE HYDROCHLORIDE (UNII: JY0WD0UA60) (MEMANTINE - UNII:W8O17SJF3T)
Camber Pharmaceuticals, Inc.
ORAL
PRESCRIPTION DRUG
Memantine hydrochloride tablets are indicated for the treatment of moderate to severe dementia of the Alzheimer’s type. Memantine hydrochloride tablet is contraindicated in patients with known hypersensitivity to memantine hydrochloride or to any excipients used in the formulation. Risk Summary There are no adequate data on the developmental risk associated with the use of memantine hydrochloride in pregnant women. Adverse developmental effects (decreased body weight, and skeletal ossification) were observed in the offspring of rats administered memantine during pregnancy at doses associated with minimal maternal toxicity. These doses are higher than those used in humans at the maximum recommended daily dose of memantine hydrochloride [see Data]. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. The background risk of major birth defects and mi
5 mg Tablets: Tan colored, modified capsule shaped, biconvex, film coated tablets debossed with 'J' on one side and '47' on the other side. Bottles of 60 NDC 31722-807-60 Bottles of 200 NDC 31722-807-02 Carton of 100 (10 x 10) Unit dose tablets NDC 31722-807-32 10 mg Tablets: Gray colored, modified capsule shaped, biconvex, film coated tablets debossed with 'J' on one side and '48' on the other side. Bottles of 60 NDC 31722-808-60 Bottles of 200 NDC 31722-808-02 Carton of 100 (10 x 10) Unit dose tablets NDC 31722-808-32 Storage: Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].
Abbreviated New Drug Application
MEMANTINE HYDROCHLORIDE - MEMANTINE HYDROCHLORIDE TABLET CAMBER PHARMACEUTICALS, INC. ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE MEMANTINE HYDROCHLORIDE TABLETS SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR MEMANTINE HYDROCHLORIDE TABLETS. MEMANTINE HYDROCHLORIDE TABLETS, FOR ORAL USE INITIAL U.S. APPROVAL: 2003 INDICATIONS AND USAGE Memantine hydrochloride tablets are an N-methyl-D-aspartate (NMDA) receptor antagonist indicated for the treatment of moderate to severe dementia of the Alzheimer’s type. ( 1) DOSAGE AND ADMINISTRATION • May be taken with or without food. ( 2) • Initial dose is 5 mg once daily. Increase dose in 5 mg increments to a maintenance dose of 10 mg twice daily. A minimum of 1 week of treatment with the previous dose should be observed before increasing the dose. ( 2) • Severe renal impairment: recommended dose is 5 mg twice daily. ( 2) DOSAGE FORMS AND STRENGTHS • Tablets: 5 mg and 10 mg ( 3) CONTRAINDICATIONS • Memantine hydrochloride tablets are contraindicated in patients with known hypersensitivity to memantine hydrochloride or to any excipients used in the formulation. ( 4) WARNINGS AND PRECAUTIONS • Conditions that raise urine pH may decrease the urinary elimination of memantine, resulting in increased plasma levels of memantine. ( 5.1, 7.1) ADVERSE REACTIONS • Most common adverse reactions (≥ 5 % and greater than placebo) are dizziness, headache, confusion and constipation. ( 6.1) TO REPORT SUSPECTED ADVERSE REACTIONS, CONTACT ANNORA PHARMA PRIVATE LIMITED AT 1- 866-495-1995 OR FDA AT 1-800-FDA-1088 OR WWW.FDA.GOV/MEDWATCH. SEE 17 FOR PATIENT COUNSELING INFORMATION. REVISED: 8/2022 FULL PRESCRIBING INFORMATION: CONTENTS* 1 INDICATIONS AND USAGE 2 DOSAGE AND ADMINISTRATION 3 DOSAGE FORMS AND STRENGTHS 4 CONTRAINDICATIONS 5 WARNINGS AND PRECAUTIONS 5.1 Genitourinary Conditions 6 ADVERSE REACTIONS 6.1 Clinical Trials Experience 6.2 Postmarketing Experience 7 DRUG INTERACTIONS 7.1 Drug Read the complete document